ArticleRMD open2017
Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease.
Article in RMD open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Effectiveness of tocilizumab monotherapy for IgG4-related disease-like features caused by idiopathic multicentric Castleman's disease: a case-based review.Rheumatology international · 2026Review
- Inflammatory Aortopathies in Rheumatic Diseases: A State-of-the-Art Review.Diagnostics (Basel, Switzerland) · 2026Review
- The Utility of IgG4/IgG Ratio in the Diagnosis of Multicentric Castleman Disease: A Case Report of HHV8+ Castleman Disease in a Patient with Classical Hodgkin's Lymphoma.Hematology reports · 2026Article
- IgG4 plasma cells in hematopathology: beyond IgG4-related disease.Journal of hematopathology · 2025Review
- IgG4-Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets.Allergy · 2025Review
- Idiopathic Multicentric Castleman Disease Diagnosed after Lower Extremity Venous Thrombosis Mimicking Immunoglobulin G4-related Disease.Internal medicine (Tokyo, Japan) · 2025Article
- Idiopathic Multicentric Castleman's Disease as a Mimicker of IgG4-related Disease.Internal medicine (Tokyo, Japan) · 2025Article
- Pharmacological Management of IgG4-Related Disease: From Traditional to Mechanism-Based Targeted Therapies.Drugs & aging · 2025Review
- Article
- Connecting the dots in a case of multiple lymphadenopathies: IgG4-related disease or Castleman disease?Internal and emergency medicine · 2025Article
- Castleman disease misdiagnosed as immunoglobulin G4-related disease: a case report.Frontiers in immunology · 2025Article
- Unraveling the complexity of IgG4-related aortitis and periarteritis: from pathogenesis to clinical practice.Frontiers in immunology · 2025Review
- A Case of Castleman's Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium.Diagnostics (Basel, Switzerland) · 2024Article
- Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.CEN case reports · 2023Article
- Diffuse cryptococcal pneumonia in multicentric Castleman's disease with elevated serum IgGBMJ case reports · 2023Article
- Pictorial review of computed tomography and magnetic resonance imaging findings of cardiovascular manifestations of IgG4-related disease.Polish journal of radiology · 2023Review
- Report of Two Cases of Pediatric IgG4-Related Lymphadenopathy (IgG4-LAD): IgG4-Related Disease (IgG4-RD) or a Distinct Clinical Pathological Entity?Children (Basel, Switzerland) · 2022Article
- Idiopathic Multicentric Castleman Disease with Strikingly Elevated IgG4 Concentration in the Serum and Abundant IgG4-Positive Cells in the Tissue: A Case Report.Diagnostics (Basel, Switzerland) · 2022Article
- The differential diagnosis of IgG4-related disease based on machine learning.Arthritis research & therapy · 2022Article
- Immunoglobulin G4-related lymph node disease with an orbital mass mimicking Castleman disease: A case report.World journal of clinical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDifferentiating IgG4-related disease (IgG4-RD) from multicentric Castleman's disease (MCD) is challenging because both diseases present high serum IgG4. The objective of this study is to clarify the differences in characteristics and identify a clinically useful approach to differentiate these two diseases.
methodsForty-five consecutive patients with untreated active IgG4-RD and 33 patients with MCD were included in this study, who visited our institution from January 2000 to August 2016. The clinical and laboratory findings for the patients of the two diseases were compared. Various combinations of the distinctive findings were evaluated to identify the most efficient differentiating features between IgG4-RD and MCD.
resultsThe levels of serum IgG4 were not different between the two diseases. Orbits, lacrimal glands, salivary glands or pancreas were involved in 88.9% of IgG4-RD cases and only in 3.0% of MCD cases. All MCD cases involved lymph nodes. Atopic history was characteristic for IgG4-RD. The levels of C reactive protein (CRP) with a cut-off of 0.80 mg/dL and IgA with a cut-off of 330 mg/dL were the most distinctive. The combination of 'Orbits, lacrimal glands, salivary glands or pancreas involvement, atopic history, or non-involvement of lymph node' and 'CRP ≤ 0.8 mg/dL or IgA ≤ 330 mg/dL' yielded the probability of 97.8% in IgG4-RD, while that of 3.0 % in patients with MCD.
conclusionsOur study revealed distinct features between IgG4-RD and MCD. Differentiating between the diseases based on those distinct features, including distribution of organ involvement, atopic history, levels of IgA and CRP, was a useful approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.